Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 9/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600160 | 0.86 | GPR84 (0.35) | GPR84KDM4EKMT2AALDH1A1HTT | |
| SCHEMBL601078 | 0.86 | ALDH1A1 (0.42) | GPR84KDM4EALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL601767 | 0.85 | ESR1 (0.40) | GPR84KDM4EKMT2AALDH1A1HTT | |
| SCHEMBL600103 | 0.81 | GPR84 (0.37) | GPR84KDM4EKMT2AALDH1A1HTT | |
| SCHEMBL599996 | 0.79 | GPR84 (0.34) | GPR84HTTCYP2D6CYP2C19PTGDR2 | |
| SCHEMBL3562505 | 0.75 | GPR84 (0.36) | GPR84ALDH1A1HTTLMNAMAPK1 | |
| SCHEMBL28093256 | 0.73 | KDM4E (0.33) | KDM4EKMT2AALDH1A1HTTCYP2D6 | |
| SCHEMBL599628 | 0.72 | GPR84 (0.35) | GPR84KDM4EALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL6841716 | 0.70 | SMN1; SMN2 (0.34) | ALDH1A1 | |
| SCHEMBL13313250 | 0.70 | ALDH1A1 (0.56) | KDM4EKMT2AALDH1A1HTTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2420500-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | aRigen Pharmaceuticals, Inc. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120041030-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | LINK GENOMICS, INC. (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041030-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | TPMT, TST, PTPN11 | GPR84 3620/4885KDM4E 3364/4885KMT2A 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.